Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Dec 28, 2022
Date Accepted: Dec 5, 2023

The final, peer-reviewed published version of this preprint can be found here:

Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study

Zheng D, Shang Y, Ni J, Peng L, Tan X, Dai Z, Zhao Y, Gu A, Wang J, Song Y, Li X, Zhang J, Heng W, Zhang C, Liu C, Li H, Du Y, Xu J, Wu D, Cai X, Meng R, Dong X, Ruan Y, Jiang L

Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study

JMIR Cancer 2024;10:e45331

DOI: 10.2196/45331

PMID: 38838304

PMCID: 11187506

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Effectiveness of Building a Telehealth Platform for Comprehensive Live-fed Real-World Data of Lung Cancer

  • Di Zheng; 
  • Yanhong Shang; 
  • Jian Ni; 
  • Ling Peng; 
  • Xiaoming Tan; 
  • Zhaoxia Dai; 
  • Yizhuo Zhao; 
  • Aiqin Gu; 
  • Jiying Wang; 
  • Yanyan Song; 
  • Xiaofeng Li; 
  • Junping Zhang; 
  • Wei Heng; 
  • Cuiying Zhang; 
  • Chunling Liu; 
  • Hui Li; 
  • Yingying Du; 
  • Jianfang Xu; 
  • Dan Wu; 
  • Xuwei Cai; 
  • Rui Meng; 
  • Xiaorong Dong; 
  • Yaoping Ruan; 
  • Liyan Jiang

ABSTRACT

Background:

Telehealth has emerged as an effective channel providing outpatient services in many countries. However, majority telehealth systems focus on operational functions offering sectional patient journey at the most. How to achieve comprehensive yet longitudinal real-world data by taking advantage of telehealth is yet to be studied.

Objective:

The primary purpose of this study is to understand the feasibility and benefits of building a live-fed longitudinal lung cancer real-world data platform supplemental to hospital electronic medical records systems.

Methods:

A telehealth platform was built and launched for physician and patient registration. Real-world data was collected and curated using a comprehensive data model. Patient stratification was performed directly from the database for statistical analysis.

Results:

Over a period of 15 months, 16035 unique users (13888 patients, 1539 friends and family members, 608 physicians) were registered. 232195 messages including EMRs and ePROs were curated and entered in the database, using medical records from 9907 patients as a basis. Comprehensive and longitudinal diagnosis and treatment data were established for 46% of the patients at the time of writing. Patient demographics from the database show the current treatment journey and practices of lung cancer in China.

Conclusions:

This study indicates that a well-designed telehealth platform is feasible to acquire live- fed longitudinal real-world data, which further empowers physicians to effectively manage patients’ treatments and engagement.


 Citation

Please cite as:

Zheng D, Shang Y, Ni J, Peng L, Tan X, Dai Z, Zhao Y, Gu A, Wang J, Song Y, Li X, Zhang J, Heng W, Zhang C, Liu C, Li H, Du Y, Xu J, Wu D, Cai X, Meng R, Dong X, Ruan Y, Jiang L

Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study

JMIR Cancer 2024;10:e45331

DOI: 10.2196/45331

PMID: 38838304

PMCID: 11187506

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.